Home LiteratureArticle Details
PMID: 26216968 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.

Skora AD, Douglass J, Hwang MS, Tam AJ, Blosser RL, Gabelli SB, Cao J, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S

Abstract

Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We here describe an approach to identify single-chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by HLA molecules. We demonstrate that these scFvs can be successfully converted to full-length antibodies, termed MANAbodies, targeting "Mutation-Associated Neo-Antigens" bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for mutant peptides bound to predefined HLA types. In this way, we obtained two scFvs, one specific for a peptide encoded by a common KRAS mutant and the other by a common epidermal growth factor receptor (EGFR) mutant. The scFvs bound to these peptides only when the peptides were complexed with HLA-A2 (KRAS peptide) or HLA-A3 (EGFR peptide). We converted one scFv to a full-length antibody (MANAbody) and demonstrate that the MANAbody specifically reacts with mutant peptide-HLA complex even when the peptide differs by only one amino acid from the normal, WT form.

Keywords
antibody engineering immunotherapy oncogene personalized therapy
MeSH Terms
Cell Membrane/metabolism Cell Surface Display Techniques Clone Cells Epitopes/genetics,immunology HLA Antigens/genetics,immunology Humans Mutant Proteins/metabolism Mutation/genetics Peptides/metabolism Single-Chain Antibodies/immunology
Chemicals
Epitopes HLA Antigens Mutant Proteins Peptides Single-Chain Antibodies
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Skora Andrew D
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; Howard Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Douglass Jacqueline
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Hwang Michael S
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Tam Ada J
Oncology Flow Cytometry Core Facility, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Blosser Richard L
Oncology Flow Cytometry Core Facility, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Gabelli Sandra B
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Cao Jianhong
Fred Hutchinson Cancer Research Center, Seattle, WA 98109.
Diaz Luis A
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Papadopoulos Nickolas
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Kinzler Kenneth W
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Vogelstein Bert
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; Howard Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; bertvog@gmail.com sbzhou@jhmi.edu.
Zhou Shibin
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; bertvog@gmail.com sbzhou@jhmi.edu.
References (60)
60 references, click to expand
  1. Mutant ras epitopes as targets for cancer vaccines.
    Semin Oncol. 1996 Feb;23(1):118-34 PMID: 8607022
  2. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Curr Opin Pharmacol. 2008 Aug;8(4):419-26 PMID: 18644254
  3. An integrated approach to extreme thermostabilization and affinity maturation of an antibody.
    Protein Eng Des Sel. 2013 Feb;26(2):151-64 PMID: 23173178
  4. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11.
    Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W509-12 PMID: 18463140
  5. Structural consensus among antibodies defines the antigen binding site.
    PLoS Comput Biol. 2012;8(2):e1002388 PMID: 22383868
  6. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.
    Immunogenetics. 1985;21(3):235-46 PMID: 3872841
  7. Beyond natural antibodies: the power of in vitro display technologies.
    Nat Biotechnol. 2011 Mar;29(3):245-54 PMID: 21390033
  8. Cancer therapy with bispecific antibodies: Clinical experience.
    Curr Opin Mol Ther. 2010 Jun;12(3):340-9 PMID: 20521223
  9. Off-rate screening for selection of high-affinity anti-drug antibodies.
    Anal Biochem. 2013 Oct 15;441(2):208-13 PMID: 23906643
  10. Flow cytometry: a versatile tool for all phases of drug discovery.
    Drug Discov Today. 1999 Apr;4(4):173-180 PMID: 10322276
  11. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
    Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6 PMID: 18287029
  12. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries.
    J Mol Biol. 2007 Nov 2;373(4):924-40 PMID: 17825836
  13. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions.
    J Mol Biol. 2004 Apr 23;338(2):299-310 PMID: 15066433
  14. The structural basis of antibody-antigen recognition.
    Front Immunol. 2013 Oct 08;4:302 PMID: 24115948
  15. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.
    Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14759-64 PMID: 16203977
  16. Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
    PLoS One. 2010;5(5):e10604 PMID: 20498701
  17. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.
    Cancer Immunol Immunother. 2012 Sep;61(9):1359-71 PMID: 22833104
  18. Antibody therapeutics in cancer.
    Science. 2013 Sep 13;341(6151):1192-8 PMID: 24031011
  19. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Int J Cancer. 1998 Jul 17;77(2):251-6 PMID: 9650561
  20. A naturally processed peptide presented by HLA-A*0201 is expressed at low abundance and recognized by an alloreactive CD8+ cytotoxic T cell with apparent high affinity.
    J Immunol. 1997 Jun 15;158(12):5797-804 PMID: 9190931
  21. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Science. 2011 Mar 25;331(6024):1565-70 PMID: 21436444
  22. T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment.
    PLoS One. 2012;7(8):e43746 PMID: 22916301
  23. Structural classification of CDR-H3 revisited: a lesson in antibody modeling.
    Proteins. 2008 Nov 15;73(3):608-20 PMID: 18473362
  24. Epitope landscape in breast and colorectal cancer.
    Cancer Res. 2008 Feb 1;68(3):889-92 PMID: 18245491
  25. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.
    J Exp Med. 2004 Aug 2;200(3):297-306 PMID: 15289501
  26. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
    J Transl Med. 2014;12:55 PMID: 24565030
  27. The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins.
    ACS Chem Biol. 2009 May 15;4(5):325-34 PMID: 19298050
  28. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
    Nat Med. 2013 Jun;19(6):747-52 PMID: 23644516
  29. Epidermal growth factor receptor mutations in lung cancer.
    Nat Rev Cancer. 2007 Mar;7(3):169-81 PMID: 17318210
  30. A genetic model for colorectal tumorigenesis.
    Cell. 1990 Jun 1;61(5):759-67 PMID: 2188735
  31. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
    Biochem Biophys Res Commun. 2009 Dec 18;390(3):547-51 PMID: 19818334
  32. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.
    Immunity. 1997 Jun;6(6):715-26 PMID: 9208844
  33. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
    Nature. 2014 Nov 27;515(7528):572-6 PMID: 25428506
  34. Proteome sampling by the HLA class I antigen processing pathway.
    PLoS Comput Biol. 2012;8(5):e1002517 PMID: 22615552
  35. Engineering T cells for cancer: our synthetic future.
    Immunol Rev. 2014 Jan;257(1):7-13 PMID: 24329786
  36. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.
    J Mol Biol. 1993 Feb 20;229(4):969-95 PMID: 8095303
  37. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).
    Oncoimmunology. 2012 Sep 1;1(6):863-873 PMID: 23162754
  38. Crystal structures of HLA-A*0201 complexed with antigenic peptides with either the amino- or carboxyl-terminal group substituted by a methyl group.
    Proteins. 1998 Oct 1;33(1):97-106 PMID: 9741848
  39. Design and construction of synthetic phage-displayed Fab libraries.
    Methods Mol Biol. 2009;562:17-35 PMID: 19554284
  40. Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation.
    J Immunol. 2001 Sep 1;167(5):2529-37 PMID: 11509592
  41. Clinical application of genetically modified T cells in cancer therapy.
    Clin Transl Immunology. 2014 May 16;3(5):e16 PMID: 25505964
  42. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
    Clin Cancer Res. 2009 May 1;15(9):3023-8 PMID: 19366827
  43. Monoclonal antibodies: versatile platforms for cancer immunotherapy.
    Nat Rev Immunol. 2010 May;10(5):317-27 PMID: 20414205
  44. Detection and quantification of rare mutations with massively parallel sequencing.
    Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5 PMID: 21586637
  45. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
    Blood. 2010 Aug 19;116(7):1035-44 PMID: 20439624
  46. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
    Nature. 2014 Nov 27;515(7528):577-81 PMID: 25428507
  47. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.
    J Clin Oncol. 2011 May 20;29(15):2066-70 PMID: 21482987
  48. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
    J Immunol. 2010 Feb 15;184(4):2156-65 PMID: 20065111
  49. Humanization of an anti-p185HER2 antibody for human cancer therapy.
    Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9 PMID: 1350088
  50. Cancer genome landscapes.
    Science. 2013 Mar 29;339(6127):1546-58 PMID: 23539594
  51. High-throughput screening of single-chain antibodies using multiplexed flow cytometry.
    J Proteome Res. 2007 Mar;6(3):1072-82 PMID: 17330944
  52. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines.
    J Immunol. 1993 Oct 1;151(7):3407-19 PMID: 8376783
  53. Origin and plasticity of MHC I-associated self peptides.
    Autoimmun Rev. 2012 Jul;11(9):627-35 PMID: 22100331
  54. High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer.
    Mod Pathol. 2014 Dec;27(12):1590-8 PMID: 24762545
  55. The influence of antibody fragment format on phage display based affinity maturation of IgG.
    MAbs. 2014 Jan-Feb;6(1):204-18 PMID: 24262918
  56. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers.
    Bioinformatics. 2008 Jun 1;24(11):1397-8 PMID: 18413329
  57. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations.
    Protein Sci. 2003 May;12(5):1007-17 PMID: 12717023
  58. Exploiting the mutanome for tumor vaccination.
    Cancer Res. 2012 Mar 1;72(5):1081-91 PMID: 22237626
  59. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.
    Blood. 2006 May 1;107(9):3779-86 PMID: 16391015
  60. Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231.
    Hum Immunol. 2000 Mar;61(3):334-40 PMID: 10689125
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2015-08-11
Epub
2015-00-27
Pages
9967-72
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC4538619
Subset
IM
Grants
NCI NIH HHS · R37 CA043460 · United States
NIGMS NIH HHS · T32 GM007309 · United States
NCI NIH HHS · P30 CA015704 · United States
NCI NIH HHS · P50 CA062924 · United States
NCI NIH HHS · CA043460 · United States
NCI NIH HHS · CA062924 · United States
Howard Hughes Medical Institute · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com